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Background: The results of previous studies assessing the association between the 5-HTTLPR polymorphism of
serotonin transporter gene and irritable bowel syndrome (IBS) are inconsistent. The aim of this study was to clarify
the association between the 5-HTTLPR mutation and the presence of IBS and its subtypes with a meta-analysis of
25 studies.
Methods: A thorough search for case–control studies evaluating the association between the 5-HTTLPR polymorphism
of serotonin transporter gene and the presence of IBS was carried out in four electronic databases. A meta-analysis was
performed in accordance with the Cochrane Handbook for systemic reviews.
Results: A total of 25 articles with 3443 IBS cases and 3359 controls were included into our meta-analysis. No significant
association was found between this polymorphism and IBS in all populations. Whereas the LL genotype was
demonstrated to be a risk factor for constipation predominant IBS (IBS-C) development in the overall population
(LL vs SS: OR = 1.570, 95% CI = 1.147-2.148, P = 0.005, Bon = 0.030; LL vs LS: OR = 1.658, 95% CI = 1.180-2.331, P = 0.004,
Bon = 0.024; LL vs LS/SS: OR = 1.545, 95% CI = 1.187-2.012, P = 0.001, Bon = 0.006). In the analysis of different ethnicities,
L allele and LL genotype were significantly associated with increased IBS-C risk in the East Asian population (L vs S:
OR = 1.487, 95% CI = 1.139-1.941, P = 0.003, Bon = 0.018; LL vs SS: OR = 2.575, 95% CI = 1.741-3.808, P = 0.000,
Bon = 0.000; LL vs LS: OR = 3.084, 95% CI = 2.017-4.715, P = 0.000, Bon = 0.000; LL vs LS/SS: OR = 2.759, 95% CI = 1.933-3.938,
P = 0.000, Bon = 0.000), but not in the Caucasian population.
Conclusions: Different from the conclusions of the earlier meta-analyses, the 5-HTTLPR mutation affects IBS-C but not
IBS-D and IBS-M development and this effect only exists in the East Asian population but not other populations.Background
Irritable bowel syndrome (IBS) mainly affecting lower
gastrointestinal (GI) tracts is a chronic functional GI dis-
order with an obvious heterogeneity among affected pa-
tients. The characteristic presentation of IBS is recurrent
abdominal pain accompanied with altered bowel habits
[1,2]. According to the Rome III criteria, IBS is categorized
into diarrhea predominant IBS (IBS-D), constipation pre-
dominant IBS (IBS-C), mixture of diarrhea and constipa-
tion IBS (IBS-M) and un-subtyped IBS [3]. IBS is a
common disorder encountered by gastroenterologists and
its prevalence is approximately 10% [4]. IBS can impair the* Correspondence: cathydoctor@yahoo.com
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Due to the elusive etiology of IBS, there is still no curative
therapy for this condition. Therapy for relieving symptoms
is still the mainstay for IBS patients. Long term symptom-
atic treatment results in an economic burden on not only
patients and their families but also healthcare systems [5].
Despite lacking of the definite etiology, some advance-
ments have been achieved in understanding the patho-
physiology underlying IBS development in recent years.
Gut motility dysfunction, visceral hypersensitivity and psy-
chopathological factors have been implicated to play key
roles in the development of IBS [1,3].
Serotonin is a neurotransmitter existing in both central
nervous system (CNS) and GI tracts, and regulates GI
tracts motility, visceral sensation and mucosal secretion
through a paracrine signaling pathway [6]. Previous studiesLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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with IBS-D and decreased plasma serotonin is associated
with IBS-C [7]. Once serotonin is secreted from ente-
rochromaffin (EC) cells, serotonin reuptake transporter
(SERT) will be activated to reuptake serotonin back into
EC cells and attenuate the effect of serotonin in GI tracts
subsequently [8]. Balance between these two opposite pro-
cesses determining the net tone of serotonin in GI tracts is
critical to the maintenance of normal gut functions, espe-
cially of GI tracts motility. Changes of the SERT activity
would break this balance and could be involved in the de-
velopment of IBS theoretically. A polymorphism of SERT
gene (5-HTTLPR) with a short (S) variation of 14 repeats
and a long (L) variation of 16 repeats has been proven to
influence the activity of SERT [9-11]. So 5-HTTLPR is very
likely to be associated with the development of IBS. Case–
control studies about 5-HTTLPR were conducted to verify
this hypothesis. Some studies demonstrated a positive as-
sociation between this polymorphism and IBS [10,11],
while another study failed to confirm this association [12].
A meta-analysis of 8 studies conducted in 2007 tried to
reach a definite conclusion and showed a negative result
[13]. However, the small sample size of this meta-analysis
weakened its strength of evidence and this meta-analysis
did not terminate the controversy about 5-HTTLPR in
IBS development. Another meta-analysis published in a
letter showed a positive association between this poly-
morphism and IBS-C [14]. However, this meta-analysis did
not include all the published articles and did not assess the
association in different ethnic groups. The third one in-
cluded most of the publish articles and concluded that
5-HTTLPR was associated with IBS [15]. The third meta-
analysis also had limitations and did not assess the associ-
ation in different IBS subtypes. The association may be
different in different IBS subtypes and different ethnic
groups. Hence we performed this meta-analysis including
all published studies accompanied with ethnic subgroup
analyses and IBS subtype analyses to clarify whether 5-




Case–control studies evaluating the association between
the 5-HTTLPR polymorphism and IBS were searched in
PubMed, Embase and Web of Science with the combina-
tions of the following searching terms: “irritable bowel
syndrome”, “IBS”, “serotonin”, “5-Hydroxytryptamine”, “5-
HT”, “polymorphism”, “polymorphisms”, “single nucleo-
tide”, “allele” and “genotype”. We also searched China
National Knowledge Infrastructure (CNKI) for additional
relevant researches. Reference lists of each article, relevant
meta-analyses and reviews were searched as well. The last
searching date was July 12, 2013.Study selection criteria
Studies included in this meta-analysis fulfilled the fol-
lowing selection criteria: 1) Case–control studies with a
healthy control arm. 2) Studies evaluating the associ-
ation between the 5-HTTLPR polymorphism and IBS.
3) IBS diagnosis according to Rome I or II or III criteria.
4) Articles providing allele and genotype frequencies or
odds ratios (OR) and 95% confidence intervals (95% CI).
Exclusion criteria were as the follows: 1) Republication.
2) Family based studies. If the data of a study was pub-
lished in different articles, the article with the largest
sample size would be included in this meta-analysis. If
the data of a study was published not only as an abstract
but also as a full text article in different magazines, we
selected the full text article to analyze in order to assess
the quality of the research more comprehensively. Dur-
ing study selection, two authors would read the highly
relevant articles independently to determine eligible stud-
ies. A third author would be consulted and the decision
would be reached through discussions when a disagree-
ment was encountered.
Data abstraction
A standard data extraction form was used to abstract
data by two investigators. And the data extraction items
included: first author, publication year, region where the
study was conducted, ethnicity, case and control defin-
ition, allele and genotype frequencies in each group and
the method of polymorphism detection. When we en-
countered an article neither in English nor in Chinese,
would a professional translator be consulted to interpret
the article.
Assessment of the risks of bias
Risks of bias were assessed with the following items: 1)
Selection bias (cases and controls selections; selections
based on disease subtypes), 2) Information bias (geno-
typing quality control procedures, genotyping under
blind conditions and phenotype misclassification rate),
3) Confounding factors (ethnic origin between cases and
controls, age and gender distribution between cases and
controls).
Quantitative data synthesis
Hardy-Weinberg equilibrium in the control group of each
study was assessed using the chi-square test, while P <
0.05 was considered disequilibrium. Paired combinations
of genotypes were used to determine the hereditary
models: 1) an allelic analysis (L versus S); 2) a genotypic
analysis (LL versus SS, LL versus LS, LS versus SS) and 3)
another genotypic analysis evaluating dominant or reces-
sive effects of allele L (LL versus LS/SS, LL/LS versus SS).
OR and its 95% CI were calculated with the methods rec-
ommended by the Cochrane Collaboration [14]. Statistical
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with a value of P < 0.10 indicating heterogeneity existence.
The I2 statistics was also employed to assess the risks of
heterogeneity: 0%-40% meant no risk of heterogeneity,
30%-60% meant a low risk of heterogeneity, 50%-90%
meant substantial heterogeneity and 75%-100% meant
considerable heterogeneity [16]. The I2 statistics less than
40% was used as the threshold to determine heterogeneity
existence in this meta-analysis. If the Q test and the I2
statistics both indicated no existence of heterogeneity, a
fixed model with the Mantel-Haenszel method would be
employed to pool data. Otherwise, a random model with
the DerSimonian-Laird method would be applied to
synthesize data. Funnel plots and Egger’s test were used to
examine publication bias [17,18]. The step down Bonferroni
method was used for the multiple comparison adjust-
ments [19]. Moreover, Student’s t test and box plots were
used to determine allele L variations among different eth-
nicities. Stata 11.0 software (StataCorp LP, College Station,
Texas, USA) was used for meta-analysis, Hardy-Weinberg
equilibrium (HWE) tests, Egger’s test, Student’s t test and
box plots drawing. R 2.15.0 software (The R Foundation
for Statistical Computing, http://cran.rstudio.com/) was
used for step down Bonferroni adjustments (Bon). Values
of P < 0.05 were considered statistically significant for
meta-analyses, Bonferroni adjustments, Egger’s test and
Student’s t test.Results and discussion
Results
Characteristics of selected studies
A total of 372 potentially relevant publications were
identified from the four databases (PubMed: 73; Web of
Science: 124; Embase: 165; CNKI: 10). After excluding
studies not fulfilling our inclusion criteria including two
abstracts not providing genotype frequencies, we in-
cluded 25 articles (3 abstracts and 22 full text articles)
with 3443 IBS cases and 3359 controls into our meta-
analysis [10-12,20-41]. Among the selected studies, 11
studies were conducted in the Caucasian population, 9
studies were conducted in the East Asian population,
two studies was conducted in the Indian population, one
study was conducted in the Iranian population, one
study was conducted in the Turkish population and one
study was conducted in the Mexican population. In
searching reference lists, relevant meta-analyses and re-
views, no additional articles were identified. The flow
chart of study selection is presented in Figure 1. And
the characteristics of selected studies are illustrated
in Table 1. The PRISMA Statement is illustrated in
Additional file 1. The searching processes of Pubmed,
Embase and Web of Science are illustrated in Additional
file 2.Assessment of the risks of bias
Selection bias IBS cases were diagnosed and selected in
accordance with the Rome criteria. Because of the evolution
of the Rome criteria, all of the three Rome criteria were
used by studies included in our meta-analysis. Two studies
used Rome I criteria to diagnose IBS [10,20], thirteen stud-
ies used Rome II criteria to diagnose IBS [11,21-31,33], nine
studies used Rome III criteria to diagnose IBS [32,34-41]
and one study selected patients from an IBS database [14].
Only four studies provided detailed descriptions of match-
ing methods [22,23,26,28]. Measures were used to exclude
IBS in controls in only seven studies [12,22,26,27,31,35,38].
Most studies selected IBS patients based on IBS subtypes
[10-12,20-31,34-41].
Information bias Twenty four studies used allele-specific
polymerase chain reaction (AS-PCR) to determine geno-
types [10-12,20-31,33-41]. One study used polymerase
chain reaction-restriction fragment length polymorphism
(PCR-RFLP) to detect genotypes [32]. Two researches were
carried out under blind conditions [30,39]. Four studies
used the DNA sequencing method to confirm genotypes
[11,12,34,41]. All experiments were repeated to ensure
consistency for quality control purposes in one study [25].
No phenotype misclassification was reported in the se-
lected studies.
Confounding factors Age and gender distributions were
comparable among arms in nine studies [11,22,23,26,28,
31,34,35,37], while the other studies did not describe the
age and gender distributions among groups. All studies
matched cases and controls ethnically.
Meta-analysis of the association between 5-HTTLPR
polymorphism and IBS
Detailed meta-analysis results, models used in each
comparison and P values for Bonferroni adjustment are
shown in Table 2 and Table 3. A wide variation of allele
L frequency between the East Asian population and the
Caucasian population was found. L allele frequency of
the East Asian population controls (29.627%, 95% CI =
19.532%-39.721%) was significantly lower than that of
the Caucasian population controls (52.182%, 95% CI =
45.166%-59.198%) (P = 0.0003). The box plots are illus-
trated in Figure 2.
Meta-analysis about IBS
No significant association was found between this poly-
morphism and IBS in the overall population. In the analysis
of the Caucasian population, only the LL vs LS contrast
showed a positive result (OR = 1.288, 95% CI = 1.079-1.536,
P = 0.005, Bon = 0.030). There was no association between
the 5-HTTLPR polymorphism and IBS in the East Asian,
Iranian, Turkish, Indian and Mexican population.
Figure 1 Flow diagram of the study selection process.
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The LL genotype was a risk factor for IBS-C develop-
ment in the overall population (LL vs SS: OR = 1.570,
95% CI = 1.147-2.148, P = 0.005, Bon = 0.030; LL vs LS:
OR = 1.658, 95% CI = 1.180-2.331, P = 0.004, Bon = 0.024;
LL vs LS/SS: OR = 1.545, 95% CI = 1.187-2.012, P = 0.001,
Bon = 0.006). In the subgroup analysis of the East Asian
population, L allele and LL genotype were significantly
associated with increased IBS-C risk in a recessive way(L vs S: OR = 1.487, 95% CI = 1.139-1.941, P = 0.003, Bon =
0.018; LL vs SS: OR = 2.575, 95% CI = 1.741-3.808, P =
0.000, Bon = 0.000; LL vs LS: OR = 3.084, 95% CI = 2.017-
4.715, P = 0.000, Bon = 0.000; LL vs LS/SS: OR = 2.759, 95%
CI = 1.933-3.938, P = 0.000, Bon = 0.000). Forest plots with
positive results of the East Asian population are shown in
Figure 3. However, there was no significant association be-
tween this polymorphism and IBS-C development in the
Caucasian, Iranian, Turkish and Indian population. The
Table 1 Characteristics of included studies evaluating the association between the 5-HTTLPR polymorphism and the
presence of IBS




Pata C [20] 2002 Turkey Turkish Case: patients diagnosed with Rome I criteria AS-PCR
Control: healthy volunteers without detailed descriptions
of matching methods
P = 0.0196
Lee DY [21] 2004 Korea East Asian Case: patients diagnosed with Rome II criteria AS-PCR
Control: healthy controls without detailed descriptions of
matching methods
P = 0.8526
Kim HJ [12] 2004 USA Mostly Caucasian Case: patients selected from a database of 752 patients
with IBS
AS-PCR
Control: healthy controls without detailed descriptions of
matching methods
P = 0.9564
Wang BM [22] 2004 China East Asian Case: patients diagnosed with Rome II criteria AS-PCR
Control: healthy contrtols matched for age and gender P = 0.1693
Yeo A [10] 2004 North America Caucasian Case: patients diagnosed with Rome I criteria AS-PCR
Control: healthy controls without detailed descriptions of
matching methods
P = 0.7053
Zhang XM [23] 2006 China East Asian Case: patients diagnosed with Rome II criteria AS-PCR
Control: healthy controls matched for age and gender P = 0.9536
Park JM [11] 2006 Korea East Asian Case: patients diagnosed with Rome II criteria AS-PCR
Control: healthy controls without detailed descriptions of
matching methods
P = 0.1976
Whitehead WE [24] 2006 USA Mostly Caucasian Case: patients diagnosed with Rome II criteria AS-PCR
Control: healthy controls without detailed descriptions of
matching methods
P = 0.2376
Li Y [25] 2007 China East Asian Case: patients diagnosed with Rome II criteria AS-PCR
Control: healthy controls without detailed descriptions of
matching methods
P = 0.5862
Saito YA [26] 2007 USA Mostly Caucasia Case: patients diagnosed with Rome II criteria AS-PCR
Control: no IBS patients matched for age, race and gender P = 0.2372
Camilleri M [27] 2008 USA Mostly Caucasian Case: patients diagnosed with Rome II criteria AS-PCR
Control: healthy controls without detailed descriptions of
matching methods
NC
Kohen R [28] 2009 USA Mostly Caucasia Case: patients diagnosed with Rome II criteria AS-PCR
Control: healthy volunteers matched for age, race and gender P = 0.1479
Schmulson M [29] 2009 Mexico Mexican Case: patients diagnosed with Rome II criteria AS-PCR
Control: healthy controls without detailed descriptions of
matching methods
P = 0.0000
Niesler B [30] 2010 UK Caucasian Case: patients diagnosed with Rome II criteria AS-PCR
Control: healthy volunteers without detailed descriptions of
matching methods
P = 0.5492
Sikander A [31] 2009 India Indian Case: patients diagnosed with Rome II criteria AS-PCR
Control: healthy controls without detailed description of
matching methods
P = 0.4341
Markoutsaki T [32] 2011 Greek Caucasian Case: patients diagnosed with Rome III criteria PCR-RFLP
Control: healthy volunteers without detailed description of
matching methods
P = 0.6973
Jiang ZD [33] 2012 USA Mostly Caucasian Case: patients diagnosed with Rome II criteria AS-PCR
Control: healthy controls without detailed descriptions of
matching methods
P = 0.1063
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Table 1 Characteristics of included studies evaluating the association between the 5-HTTLPR polymorphism and the
presence of IBS (Continued)
Wang YM [34] 2012 China East Asian Case: patients diagnosed with Rome III criteria AS-PCR
Control: healthy controls without detailed description of
matching methods
P = 0.0000
Park CS [35] 2012 Korea East Asian Case: patients diagnosed with Rome III criteria AS-PCR
Control: healthy controls without detailed descriptions of
matching methods
P = 0.3054
Zhang ZX [36] 2012 China East Asian Case: patients diagnosed with Rome III criteria AS-PCR
Control: healthy volunteers matched for age, race and gender P = 0.4531
Kumar S [37] 2012 India Indian Case: patients diagnosed with Rome III criteria AS-PCR
Control: healthy controls without detailed descriptions of
matching methods
P = 0.3093
Saito YA [38] 2012 USA Mostly Caucasia Case: patients diagnosed with Rome III criteria AS-PCR
Control: healthy examinees matched for age, race and gender P = 0.5924
Colucci R [39] 2013 Italy Caucasian Case: patients diagnosed with Rome III criteria AS-PCR
Control: healthy controls without detailed descriptions of
matching methods
P = 0.6459
Shiotani A [40] 2013 Japan East Asian Case: patients diagnosed with Rome III criteria AS-PCR
Control: healthy controls without detailed descriptions of
matching methods
P = 0.5780
Farjadian S [41] 2013 Iran Iranian Case: patients diagnosed with Rome III criteria AS-PCR
Control: healthy examinees matched for age, race and gender P = 0.2284
SNP: single nucleotide polymorphism; PCR-RFLP: polymerase chain reaction-restriction fragment length polymorphism; AS-PCR: allele-specific polymerase chain
reaction; HWE test: Hardy-Weinberg equilibrium test; NC: not able to calculated from raw data.
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ate the effect of the 5-HTTLPR polymorphism on IBS-C
subtype.Meta-analysis about IBS-D and IBS-M
No significant association was found between this poly-
morphism and IBS-D and IBS-M in the overall popu-
lation. In subgroup analysis, there was no significant
association between this polymorphism and IBS-C and
IBS-M development in the Caucasian, East Asian, Indian
and Iranian population. In the analysis between the 5-
HTTLPR polymorphism and IBS-D in the Turkish popu-
lation, only the LS vs SS contrast showed a positive result
(OR = 8.471, 95% = 1.811-39.626, P = 0.007, Bon = 0.042).
No association was found between this polymorphism and
IBS-M development in the Turkish population. The study
conducted in the Mexican population did not evaluate
the effect of this polymorphism on IBS-D and IBS-M
subtypes.Sensitivity analysis
After excluding studies not fulfilling HWE or not pro-
viding HWE data, the conclusions of our meta-analysis
were not changed. The conclusions were not changed ei-
ther when we used both a fixed and a random model to
perform meta-analyses.Evaluation of publication bias
The Begg funnel plot was symmetry in the overall IBS
analysis, as shown in Figure 4. Begger’s test showed no
publication bias in the overall IBS analysis (P = 0.529).
Discussion
Gut motility dysfunction, visceral hypersensitivity and psy-
chopathological factors have been implicated to play key
roles in the development of IBS [1,3]. Recently, some
scholars integrated the above factors and postulated a
model called brain-gut axis (BGA), which is bi-directional
and constitutes the enteric nervous system (ENS) and the
gut wall, CNS and the hypothalamus-pituitary-adrenal
(HPA) axis [42]. BGA dysfunction at each level is believed
to be involved in the pathophysiology of IBS [43]. Psycho-
pathological factors cause gut motility dysfunction, abnor-
mal mucosa secretion and visceral hypersensitivity via
BGA and vice versa. So BGA model may be the optimal
model in understanding IBS pathophysiology and can ex-
plain most of the presentations of IBS frequently accom-
panied with psychological conditions.
Neural, endocrine and neuro-immune pathways are all
involved in BGA. And neurotransmitters are involved in
all the three pathways, so inappropriate neurotransmitter
secretion could cause BGA dysfunction and plays a key
role in IBS development. Serotonin existing in not only
GI tracts but also CNS is one of these neurotransmitters.
Table 2 Meta-analyses of the association between the 5-HTTLPR polymorphism and the presence of IBS
Ethnicity Cases/Controls L vs S LL vs SS LL vs LS
(OR,95% CI) P (Model) Bon (OR,95% CI) P (Model) Bon (OR,95% CI) P (Model) Bon
IBS
25 studies Overall 3443/3359 (0.993,0.867-1.138) P = 0.923 (R) 1.000 (1.009,0.772-1.319) P = 0.948 (R) 1.000 (1.284,1.040-1.585) P = 0.020 (R) 0.120
11 studies Cau/M Cau 1855/1590 (1.008,0.859-1.183) P = 0.919 (R) 1.000 (1.018,0.752-1.378) P = 0.907 (R) 1.000 (1.288,1.079-1.536) P = 0.005 (F) 0.030
9 studies East Asian 1138/1102 (1.151,0.901-1.471) P = 0.261 (R) 1.000 (1.371,0.764-2.461) P = 0.291 (R) 1.000 (1.528,0.849-2.751) P = 0.157 (R) 0.942
1 study Turkish 54/92 (0.934,0.577-1.514) P = 0.782 1.000 (0.727,0.271-1.952) P = 0.527 1.000 (0.442,0.171-1.143) P = 0.092 0.552
2 studies Indian 301/352 (0.687,0.375-1.259) P = 0.225 (R) 1.000 (0.588,0.241-1.435) P = 0.243 (R) 1.000 (1.077,0.669-1.733) P = 0.761 (F) 1.000
1 study Mexian 45/123 (0.482,0.256-0.910) P = 0.024 0.144 (0.290,0.082-1.030) P = 0.056 0.336 (0.313,0.073-1.337) P = 0.117 0.702
1 study Iranian 50/100 (1.083,0.670-1.751) P = 0.744 1.000 (1.168,0.466-2.931) P = 0.740 1.000 (2.246,0.976-5.165) P = 0.057 1.000
IBS-C
20 studies Overall 992/2437 (1.232,1.048-1.449) P = 0.011 (R) 0.066 (1.570,1.147-2.148) P = 0.005 (F) 0.030 (1.658,1.180-2.331) P = 0.004 (R) 0.024
8 studies Cau/M Cau 462/841 (1.270,1.060-1.520) P = 0.009 (F) 0.054 (1.627,1.109-2.388) P = 0.013 (F) 0.078 (1.269,0.956-1.685) P = 0.100 (F) 1.000
8 studies East Asian 393/1052 (1.487,1.139-1.941) P = 0.003 (R) 0.018 (2.575,1.741-3.808) P = 0.000 (F) 0.000 (3.084,2.017-4.715) P = 0.000 (F) 0.000
1 study Turkish 26/92 (0.719,0.379-1.367) P = 0.315 1.000 (0.545,0.156-1.903) P = 0.342 1.000 (0.618,0.172-2.218) P = 0.461 1.000
2 studies Indian 96/352 (0.798,0.438-1.452) P = 0.460 (R) 1.000 (0.676,0.330-1.384) P = 0.284 (F) 1.000 (0.769,0.389-1.522) P = 0.451 (F) 1.000
1 study Iranian 15/100 (0.796,0.367-1.725) P = 0.563 1.000 (0.730,0.181-2.951) P = 0.659 1.000 (2.133,0.522-8.714) P = 0.291 1.000
IBS-D
21 studies Overall 1454/2813 (0.932,0.771-1.126) P = 0.466 (R) 1.000 (0.888,0.666-1.183) P = 0.416 (R) 1.000 (1.209,0.973-1.502) P = 0.086 (R) 0.516
9 studies Cau/M Cau 806/1270 (0.986,0.863-1.126) P = 0.835 (F) 1.000 (0.921,0.706-1.200) P = 0.540 (F) 1.000 (1.251,1.005-1.556) P = 0.045 (F) 0.270
8 studies East Asian 434/999 (0.846,0.694-1.032) P = 0.099 (F) 0.594 (0.785,0.498-1.239) P = 0.299 (F) 1.000 (0.930,0.579-1.494) P = 0.764 (F) 1.000
1 study Turkish 18/92 (1.087,0.529-2.232) P = 0.820 1.000 (0.324,0.015-7.070) P = 0.474 1.000 (0.046,0.003-0.814) P = 0.036 0.216
2 studies Indian 171/352 (0.478,0.084-2.707) P = 0.404 (R) 0.828 (0.494,0.069-3.514) P = 0.481 (R) 1.000 (1.355,0.715-2.566) P = 0.351 (F) 1.000
1 study Iranian 25/100 (1.325,0.710-2.471) P = 0.377 1.000 (1.565,0.504-4.856) P = 0.439 1.000 (3.333,1.159-9.586) P = 0.025 0.150
IBS-M
17 studies Overall 486/2042 (1.087,0.911-1.296) P = 0.354 (R) 1.000 (1.170,0.830-1.651) P = 0.370 (R) 1.000 (1.313,0.991-1.740) P = 0.058 (F) 0.348
6 studies Cau/M Cau 265/549 (1.096,0.754-1.593) P = 0.630 (R) 1.000 (1.153,0.538-2.471) P = 0.714 (R) 1.000 (1.533,1.069-2.198) P = 0.020 (F) 0.120
7 studies East Asian 167/949 (1.030,0.785-1.351) P = 0.830 (F) 1.000 (1.135,0.637-2.022) P = 0.667 (F) 1.000 (0.906,0.507-1.617) P = 0.737 (F) 1.000
1 study Turkish 10/92 (2.038,0.795-5.225) P = 0.138 0.828 (4.909,0.480-50.178) P = 0.180 1.000 (0.773,0.175-3.415 P = 0.734 1.000
2 studies Indian 34/352 (1.022,0.616-1.697) P = 0.932 (F) 1.000 (1.157,0.452-2.965) P = 0.761 (F) 1.000 (1.684,0.662-4.280 P = 0.274 (F) 1.000
1 study Iranian 10/100 (1.041,0.415-2.610) P = 0.932 1.000 (1.095,0.141-8.485) P = 0.931 1.000 (0.889,0.166-4.755 P = 0.891 1.000


















Table 3 Meta-analyses of the association between the 5-HTTLPR polymorphism and the presence of IBS
Ethnicity Cases/Controls LS vs SS LL vs LS/SS LL/LS vs SS
(OR,95% CI) P (Model) Bon (OR,95% CI) P (Model) Bon (OR,95% CI) P (Model) Bon
IBS
25 studies Overall 3443/3359 (0.814,0.681-0.973) P = 0.023 (R) 0.138 (1.141,0.935-1.391) P = 0.195 (R) 1.000 (0.883,0.739-1.055) P = 0.171 (R) 1.000
11 studies Cau/M Cau 1855/1590 (0.796,0.566-1.119) P = 0.189 (R) 1.000 (1.506,1.112-2.039) P = 0.070 (F) 0.420 (0.874,0.643-1.189) P = 0.391 (R) 1.000
9 studies East Asian 1138/1102 (0.892,0.727-1.094) P = 0.272 (R) 1.000 (1.456,0.831-2.549) P = 0.189 (R) 1.000 (0.999,0.828-1.207) P = 0.995 (F) 1.000
1 study Turkish 54/92 (1.647,0.774-3.505) P = 0.195 1.000 (0.553,0.227-1.348) P = 0.193 1.000 (1.286,0.636-2.599) P = 0.484 1.000
2 studies Indian 301/352 (0.542,0.284-1.034) P = 0.063 (R) 0.378 (0.763,0.494-1.178) P = 0.223 (F) 1.000 (0.555,0.272-1.130) P = 0.105 (R) 1.000
1 study Mexian 45/123 (0.929,0.373-2.316) P = 0.875 1.000 (0.295,0.084-.032) P = 0.056 0.336 (0.581,0.268-1.259) P = 0.169 1.000
1 study Iranian 50/100 (0.520,0.226-1.197) P = 0.124 0.744 (1.770,0.824-3.803) P = 0.143 0.858 (0.697,0.325-1.495) P = 0.354 1.000
IBS-C
20 studies Overall 992/2437 (0.926,0.708-1.212) P = 0.578 (R) 1.000 (1.545,1.187-2.012) P = 0.001 (R) 0.006 (1.119,0.890-1.406) P = 0.335 (R) 1.000
8 studies Cau/M Cau 462/841 (1.266,0.883-1.815) P = 0.199 (F) 1.000 (1.327,1.027-1.715) P = 0.031 (F) 0.186 (1.398,0.994-1.968) P = 0.054 (F) 0.324
8 studies East Asian 393/1052 (0.906,0.672-1.220) P = 0.514 (F) 1.000 (2.759,1.933-3.938) P = 0.000 (F) 0.000 (1.250,0.964-1.622) P = 0.093 (F) 0.558
1 study Turkish 26/92 (0.882,0.337-2.307) P = 0.799 1.000 (0.579,0.180-1.860) P = 0.358 1.000 (0.750,0.312-1.803) P = 0.165 0.990
2 studies Indian 96/352 (0.783,0.185-3.324) P = 0.740 (R) 1.000 (0.726,0.378-1.394) P = 0.336 (F) 1.000 (0.753,0.213-2.661) P = 0.660 (R) 1.000
1 study Iranian 15/100 (0.342,0.095-1.234) P = 0.101 0.606 (1.368,0.395-4.734) P = 0.621 1.000 (0.448,0.144-1.391) P = 0.165 0.990
IBS-D
21 studies Overall 1454/2813 (0.863,0.619-1.205) P = 0.387 (R) 1.000 (1.042,0.862-1.260) P = 0.668 (R) 1.000 (0.885,0.648-1.209) P = 0.443 (R) 1.000
9 studies Cau/M Cau 806/1270 (0.854,0.548-1.332) P = 0.423 (R) 1.000 (1.113,0.914-1.357) P = 0.286 (F) 1.000 (0.922,0.626-1.357) P = 0.680 (R) 1.000
8 studies East Asian 434/999 (0.896,0.686-1.171) P = 0.423 (F) 1.000 (0.850,0.561-1.289) P = 0.444 (F) 1.000 (0.843,0.656-1.083) P = 0.181 (F) 1.000
1 study Turkish 18/92 (8.471,1.811-39.626) P = 0.007 0.042 (0.085,0.005-1.462) P = 0.089 0.534 (5.143,1.115-23.714) P = 0.036 0.096
2 studies Indian 171/352 (0.321,0.024-4.370) P = 0.394 (R) 1.000 (0.680,0.214-2.159) P = 0.513 (F) 1.000 (0.371,0.036-3.819) P = 0.405 (R) 1.000
1 study Iranian 25/100 (0.469,0.152-1.445) P = 0.187 1.000 (2.508,0.986-6.380) P = 0.054 0.324 (0.768,0.286-2.066) P = 0.601 1.000
IBS-M
17 studies Overall 486/2042 (0.920,0.706-1.199) P = 0.538 (F) 1.000 (1.186,0.887-1.584) P = 0.250 (R) 1.000 (0.971,0.760-1.242) P = 0.817 (F) 1.000
6 studies Cau/M Cau 265/549 (0.728,0.476-1.112) P = 0.142 (F) 0.852 (1.172,0.707-1.942) P = 0.539 (R) 1.000 (0.834,0.563-1.237) P = 0.368 (F) 1.000
7 studies East Asian 167/949 (1.106,0.750-1.632) P = 0.611 (F) 1.000 (1.000,0.590-1.696) P = 1.000 (F) 1.000 (1.082,0.754-1.554) P = 0.669 (F) 1.000
1 study Turkish 10/92 (6.353,0.727-55.545) P = 0.095 0.570 (1.364,0.325-5.726) P = 0.672 1.000 (5.786,0.703-47.626) P = 0.103 0.618
2 studies Indian 34/352 (0.695,0.309-1.562) P = 0.379 (F) 1.000 (1.421,0.611-3.303) P = 0.415 (F) 1.000 (0.817,0.393-1.698) P = 0.588 1.000
1 study Iranian 10/100 (1.232,0.231-6.560) P = 0.807 1.000 (0.940,0.186-4.764) P = 0.941 1.000 (1.195,0.237-6.025) P = 0.829 1.000


















Figure 2 Frequency of the L allele between the East Asian
population and the Caucasian population.
Figure 3 Meta-analyses with positive results of the association betwe
East Asian population.
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http://www.biomedcentral.com/1471-230X/14/23Changes of the serotonin levels in GI tracts can affect
visceral sensitivity and gut motility [7,44]. Previous stud-
ies have also showed that elevated plasma serotonin is
associated with IBS-D and decreased plasma serotonin is
associated with IBS-C [7]. Once serotonin is secreted
from EC cells, SERT will be activated to reuptake sero-
tonin back into EC cells and attenuate the effect of sero-
tonin in GI tracts subsequently [8]. The L variation of
5-HTTLPR is found to increase the expression of SERT
gene and enhance SERT activity consequently [9-11,34].
The enhanced SERT activity would take up serotonin
and weaken its effects in promoting gut secretion and
motility. So compared with S allele and SS genotype car-
riers, L allele and LL genotype carriers are likely to be
more susceptible to IBS-C. The results of our meta-
analysis support this hypothesis. However, the effect of
5-HTTLPR on IBS-C is population dependent and the
positive association is only present in the East Asian
population but not in the Caucasian population. We also
found that L allele frequency of the East Asian popula-
tion controls was significantly lower than that of theen the 5-HTTLPR polymorphism and the presence of IBS-C in the
Figure 4 Begg funnel plot of the overall IBS analysis LL vs LS/SS.
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http://www.biomedcentral.com/1471-230X/14/23Caucasian population controls. So the different allelic
frequency between the two populations may account for
this phenomenon. Furthermore, there is a higher preva-
lence of psychological and psychiatric disorders among
IBS patients [45]. The state of CNS can also affect the de-
velopment of IBS. However, the effect of the 5-HTTLPR
variant on CNS is different from that on GI tracts in IBS
development. A meta-analysis demonstrated that the S
variant was associated with heightened amygdala activa-
tion which would predispose S carriers to stress-related
psychiatric disorders [46]. Another meta-analysis also
showed a positive association between the S allele and an
increased risk of developing depression under stress [47].
The S allele may increase the risk of IBS-C development
through the CNS pathway. So the opposite effect of 5-
HTTLPR variant on GI tracts and CNS during IBS-C de-
velopment may also account for some variations among
studies assessing the association between the 5-HTTLPR
variant and IBS-C. Future studies should exclude the psy-
chological confounding factors or stratify analyses based
on psychological conditions. IBS may be further catego-
rized into subtypes based on psychological conditions be-
sides of the Rome criteria. Additionally, an adenine to
guanine polymorphism in the L allele has been recently
identified and only the adenine L allele but not the guan-
ine L allele is found to increase the activity of SERT [48].
This internal L allele polymorphism may attenuate the ef-
fect of the L allele on IBS-C development. Only one small
sample size study included in our meta-analysis evaluated
the effect of internal L allele polymorphism on IBS devel-
opment and showed a negative result. Future studies
should further assess the effect of the 5-HTTLPR poly-
morphism on IBS-C according to the internal L allele
polymorphism. Moreover, a study indicates that the S al-
lele is associated with higher pain sensory ratings during
rectal distension studies in healthy controls and IBSpatients, and the increased sensation ratings in carriers of
the S allele are not caused by lower rectal compliance [27].
Different genotype and allele may have different effects on
gut motility and intestinal sensation respectively. This
phenomenon also indicates the complexity of IBS and the
necessity to classifying IBS based on pathophysiology.
Clarifying genotypes of the 5-HTTLPR polymorphism
also has clinical implications. One study found that IBS-C
patients with the LL genotype responded poorly to treat-
ment with the 5-HT4 receptor agonist, tegaserod [25]. An-
other study investigating rectal smooth muscle contractions
found that IBS patients with the SS genotype showed more
increase in phasic contractions compared with patients
with the LL genotype after administration of the 5-HT4 re-
ceptor agonist, mosapride [49]. Determining the genotype
of the 5-HTTLPR polymorphism may be of value to the
prognosis and the prediction of treatment response in a
IBS-C patient.
The conclusions of this meta-analysis are a little dif-
ferent from the previous meta-analyses. As we know,
this meta-analysis is the latest one and has the largest
sample size. So the result of our meta-analysis is more
likely convincing. However, the conclusions of this
meta-analysis should be interpreted cautiously due to
some limitations. Firstly, selection bias could not be ex-
cluded as only seven studies employed measures to ex-
clude IBS in the controls. Secondly, only four studies
used the DNA sequencing method to confirm geno-
types, and two studies used blindness measures. Infor-
mation bias is inevitable. Thirdly, most of the included
studies did not describe the age and gender distribution
between cases and controls. Confounding factors could
not be excluded. Moreover, heterogeneity existed in
some contrasts which might also affect the validity of
this meta-analysis. Although the Egger’s test showed no
publication bias existing, the data of two abstracts were
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http://www.biomedcentral.com/1471-230X/14/23not included in this meta-analysis for failing to provide
genotype frequencies. Thus a reporting bias existed.
Moreover, we employed the Bonferroni adjustments
method to avoid false positive results, the risk of false
negative results occurrence would be increased. So
when interpreting the negative results of our meta-
analysis, we should be cautious.
Conclusions
In summary, in despite of the above limitations, this meta-
analysis shows a positive association between the L allele
and LL genotype of 5-HTTLPR mutation and IBS-C in
the East Asian population but not in the Caucasian popu-
lation. These results offer some insights into gene func-
tions affecting IBS susceptibility and some clues in IBS
management, especially in the East Asian population.
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